Exosome-Based Multivalent Vaccine: Achieving Potent Immunization, Broadened Reactivity, and Strong T-Cell Responses with Nanograms of Proteins
Mafalda Cacciottolo, Justin B. Nice, Yujia Li, Michael J. LeClaire, Ryan Twaddle, Ciana L. Mora, Stephanie Y. Adachi, Esther R. Chin, Meredith Young, Jenna Angeles, Kristi Elliott, Minghao Sun
Abstract
The pandemic emergency has brought to light the need for a new generation of rapidly developed vaccines that induce longer-lasting, potent, and broader immune responses. While the mRNA vaccines played a critical role during the emergency in reducing SARS-CoV-2 hospitalization rates and deaths, more efficient approaches are needed. A multivalent, protein-based vaccine delivered by exosomes could meet this urgent need due to the high speed of development, manufacturability, and the ability to produce a strong antibody response, with neutralizing antibodies and a strong T-cell response able to broadly combat viral infection with a minimum number of injections.